• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Taysha Gene Therapies Inc.

    1/6/26 4:37:54 PM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TSHA alert in real time by email
    S-8 1 d20072ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on January 6, 2026

    Registration No. 333-   

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Taysha Gene Therapies, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   84-3199512

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    3000 Pegasus Park Drive

    Suite 1430

    Dallas, Texas 75247

    (Address of principal executive offices, including zip code)

    Taysha Gene Therapies, Inc. 2020 Stock Incentive Plan

    Taysha Gene Therapies, Inc. 2020 Employee Stock Purchase Plan

    Taysha Gene Therapies, Inc. 2023 Inducement Plan

    (Full titles of the plans)

    Sean P. Nolan

    Chief Executive Officer

    3000 Pegasus Park Drive

    Suite 1430

    Dallas, Texas 75247

    (214) 612-0000

    (Name, address and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Divakar Gupta

    Madison A. Jones

    Cooley LLP

    55 Hudson Yards

    New York, New York 10001

    Telephone: (212) 479-6000

    Facsimile: (212) 479-6275

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☐

     

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    EXPLANATORY NOTE

    REGISTRATION OF ADDITIONAL SHARES

    Pursuant to General Instruction E of Form S-8, Taysha Gene Therapies, Inc. (the “Registrant”) is filing this Registration Statement on Form S-8 with the Securities and Exchange Commission (the “Commission”) for the purpose of registering (i) 14,252,582 additional shares of its common stock under the Registrant’s 2020 Stock Incentive Plan (the “2020 Plan”), pursuant to the provisions of the 2020 Plan providing for an automatic increase in the number of shares of common stock reserved and available for issuance under the 2020 Plan on January 1, 2026, (ii) 724,000 additional shares of its common stock under the Registrant’s 2020 Employee Stock Purchase Plan (the “2020 ESPP”), pursuant to the provisions of the 2020 ESPP providing for an automatic increase in the number of shares of common stock reserved and available for issuance under the 2020 ESPP on January 1, 2026 and (iii) 3,000,000 shares of its common stock under the Registrant’s 2023 Inducement Plan (the “Inducement Plan”). The additional shares of common stock under the Inducement Plan represent an increase in the number of shares of common stock reserved for issuance under the Inducement Plan, which increase was approved by the Registrant’s Board of Directors on November 14, 2025. In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.

    The Registrant previously registered shares of its common stock for issuance under the 2020 Plan and the 2020 ESPP on a Registration Statement on Form S-8 filed with the Commission on September 29, 2020 (File No.  333-249130), a Registration Statement on Form S-8 filed with the Commission on May 11, 2021 (File No. 333-256013), a Registration Statement on Form S-8 filed with the Commission on March 31, 2022 (File No. 333-264025), a Registration Statement on Form S-8 filed with the Commission on March 28, 2023 (File No. 333-270915) a Registration Statement on Form S-8 filed with the Commission on March 19, 2024 (File No. 333-278070) and a Registration Statement on Form S-8 filed with the Commission on January 7, 2025 (File No. 333-284167), and under its Inducement Plan on a Registration Statement on Form S-8 filed with the Commission on December 20, 2023 (File No.  333-276161) and on a Registration Statement on Form S-8 filed with the Commission on January 7, 2025 (File No. 333-284167). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statements referenced above except to the extent supplemented, amended or superseded by the information set forth herein.

    PART II

    INFORMATION REQUIRED IN REGISTRATION STATEMENT

     

    ITEM 3.

    INCORPORATION OF DOCUMENTS BY REFERENCE

    The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:

     

      (a)

    The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on February 26, 2025.

     

      (b)

    The information specifically incorporated by reference into the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024 from the Registrant’s Definitive Proxy Statement on Schedule 14A filed with the Commission on April 21, 2025.


      (c)

    The Registrant’s Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2025, June 30, 2025 and September  30, 2025 filed with the Commission on May  15, 2025, August  12, 2025 and November 4, 2025, respectively.

     

      (d)

    The Registrant’s Current Reports on Form 8-K filed with the Commission on May  28, 2025, May  29, 2025, June  3, 2025, October  2, 2025, October  9, 2025, October  16, 2025 and November 4, 2025, and on Form 8-K/A filed with the Commission on May 29, 2025, to the extent the information in such report is filed and not furnished.

     

      (e)

    The description of the Registrant’s common stock which is contained in the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed on August 12, 2024, including any amendment or report filed with the Commission for the purpose of updating such description.

     

      (f)

    All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14, and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.


    ITEM 8.

    EXHIBITS

     

              Incorporated by Reference  

    Exhibit

    Number

      

    Description

       Schedule
    Form
         File Number      Exhibit      Filing Date  
      4.1    Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect      8-K        001-39536        3.1       
    September 29,
    2020
     
     
      4.2    Certificate of Amendment to the Amended and Restated Certificate of Incorporation      8-K        001-39536        3.1       
    November 15,
    2023
     
     
      4.3    Certificate of Amendment to the Amended and Restated Certificate of Incorporation      8-K        001-39536        3.1        June 3, 2025  
      4.4    Amended and Restated Bylaws of the Registrant, as currently in effect      S-1/A        333-248559        3.4       
    September 17,
    2020
     
     
      5.1*    Opinion of Cooley LLP.            
     23.1*    Consent of Cooley LLP (included in Exhibit 5.1).            
     23.2*    Consent of Deloitte & Touche LLP, independent registered public accounting firm.            
     24.1*    Power of Attorney (included on the signature page of this Form S-8).            
     99.1    2020 Stock Incentive Plan and Forms of Stock Option Grant Notice, Stock Option Agreement, Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement      S-1/A        333-248559        10.6       
    September 17,
    2020
     
     
     99.2    2020 Employee Stock Purchase Plan      S-1/A        333-248559        10.7       
    September 17,
    2020
     
     
     99.3    Taysha Gene Therapies, Inc. 2023 Inducement Plan.      S-8        333-276161        99.1       
    December 20,
    2023
     
     
     99.4    Form of Option Grant Package under 2023 Inducement Plan.      S-8        333-276161        99.2       
    December 20,
    2023
     
     
     99.5    Form of RSU Grant Package under 2023 Inducement Plan.      S-8        333-276161        99.3       
    December 20,
    2023
     
     
     99.6    Amendment No. 1 to 2023 Inducement Plan      S-8        333-284167        99.6       
    January 7,
    2025
     
     
     99.7*    Amendment No. 2 to 2023 Inducement Plan            
    107*    Filing Fee Table            

     

    *

    Filed herewith.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Dallas, State of Texas, on this 6th day of January, 2026.

     

    TAYSHA GENE THERAPIES, INC.
    By:  

    /s/ Sean P. Nolan

      Sean P. Nolan
      Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Sean P. Nolan and Kamran Alam, and each one of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in their name, place or stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Name

      

    Title

      

    Date

    /s/ Sean P. Nolan

    Sean P. Nolan

      

    Chief Executive Officer and Chairman

    (Principal Executive Officer)

       January 6, 2026

    /s/ Kamran Alam

    Kamran Alam

      

    Chief Financial Officer (Principal Financial and Accounting Officer)

       January 6, 2026

    /s/ Phillip B. Donenberg

    Phillip B. Donenberg

      

    Director

       January 6, 2026

    /s/ Sean Stalfort

    Sean Stalfort

      

    Director

       January 6, 2026

    /s/ Sukumar Nagendran, M.D.

    Sukumar Nagendran, M.D.

      

    President, Head of Research and Development, and Director

       January 6, 2026

    /s/ Alison Long, M.D., Ph.D.

    Alison Long, M.D., Ph.D.

      

    Director

       January 6, 2026

    /s/ Laura Sepp-Lorenzino, Ph.D.

    Laura Sepp-Lorenzino, Ph.D.

      

    Director

       January 6, 2026
    Get the next $TSHA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TSHA

    DatePrice TargetRatingAnalyst
    10/21/2025$13.00Strong Buy
    Raymond James
    7/11/2025$8.00Buy
    BofA Securities
    6/27/2024$5.00Outperform
    BMO Capital Markets
    4/9/2024$9.00Overweight
    Piper Sandler
    2/1/2023$14.00 → $1.50Buy → Hold
    Jefferies
    1/27/2023$23.00 → $3.00Overweight → Equal-Weight
    Morgan Stanley
    11/9/2022$16.00 → $3.00Buy → Neutral
    Goldman
    3/9/2022$26.00Outperform
    Robert W. Baird
    More analyst ratings

    $TSHA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Raymond James initiated coverage on Taysha Gene Therapies with a new price target

    Raymond James initiated coverage of Taysha Gene Therapies with a rating of Strong Buy and set a new price target of $13.00

    10/21/25 7:22:35 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BofA Securities initiated coverage on Taysha Gene Therapies with a new price target

    BofA Securities initiated coverage of Taysha Gene Therapies with a rating of Buy and set a new price target of $8.00

    7/11/25 8:16:08 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BMO Capital Markets initiated coverage on Taysha Gene Therapies with a new price target

    BMO Capital Markets initiated coverage of Taysha Gene Therapies with a rating of Outperform and set a new price target of $5.00

    6/27/24 7:52:29 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TSHA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Manning Paul B bought $2,062,500 worth of shares (750,000 units at $2.75) (SEC Form 4)

    4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)

    6/3/25 9:38:27 PM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Manning Paul B bought $2,999,999 worth of shares (1,333,333 units at $2.25) (SEC Form 4)

    4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)

    7/1/24 8:00:07 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Manning Paul B bought $163,000 worth of shares (100,000 units at $1.63) (SEC Form 4)

    4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)

    11/20/23 7:35:02 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TSHA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome

    First patient dosed in REVEAL pivotal trial evaluating TSHA-102 (N=15, aged 6 to <22 years) in Q4 2025, with enrollment advancing across multiple sites Reached written alignment with FDA on inclusion of ≥3 months of safety data from ASPIRE trial evaluating TSHA-102 (N=3, aged 2 to <4 years) in planned BLA submission to support a broad label in patients aged ≥2 years with Rett syndrome Completion of dosing in REVEAL pivotal trial and ASPIRE trial expected in Q2 2026 Longer-term safety and efficacy data update from Part A of REVEAL Phase 1/2 trials expected in H1 2026 DALLAS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-s

    1/6/26 8:00:00 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    DALLAS, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on December 3, 2025, the Compensation Committee of Taysha's Board of Directors granted two new employees, in the aggregate, options to purchase 212,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Tays

    12/5/25 4:05:00 PM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    TSHA-102 granted Breakthrough Therapy designation by FDA Finalized FDA alignment on REVEAL pivotal trial protocol and SAP, including 6-month interim analysis that may expedite BLA submission, which was enabled by the rigorous developmental milestone evaluation in Part A REVEAL Phase 1/2 trials showing an unprecedented response rate Dosing of first patient in REVEAL pivotal trial scheduled for Q4 2025, with enrollment of additional patients expected to continue at multiple sites this quarter Presented new supplemental analysis of Part A REVEAL data reinforcing the broad and consistent, multi-domain impact of TSHA-102 on activities of daily living at the CNS Annual Meeting TSHA-102

    11/4/25 7:00:00 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TSHA
    SEC Filings

    View All

    SEC Form S-8 filed by Taysha Gene Therapies Inc.

    S-8 - Taysha Gene Therapies, Inc. (0001806310) (Filer)

    1/6/26 4:37:54 PM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Taysha Gene Therapies Inc.

    144 - Taysha Gene Therapies, Inc. (0001806310) (Subject)

    11/28/25 1:07:12 PM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Taysha Gene Therapies Inc.

    SCHEDULE 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)

    11/14/25 4:18:16 PM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TSHA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and Head of R&D Nagendran Sukumar exercised 370,172 shares at a strike of $1.52 and sold $1,695,906 worth of shares (370,172 units at $4.58) (SEC Form 4)

    4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)

    12/1/25 8:58:44 PM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and Head of R&D Nagendran Sukumar exercised 41,150 shares at a strike of $0.70 and sold $646,000 worth of shares (200,000 units at $3.23), decreasing direct ownership by 14% to 1,006,439 units (SEC Form 4)

    4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)

    9/12/25 4:15:25 PM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and Head of R&D Nagendran Sukumar sold $162,604 worth of shares (57,054 units at $2.85), decreasing direct ownership by 5% to 1,165,289 units (SEC Form 4)

    4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)

    8/22/25 4:15:17 PM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TSHA
    Leadership Updates

    Live Leadership Updates

    View All

    Taysha Gene Therapies Reports Full-Year 2020 Financial Results and Provides a Corporate Update

    DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today reported financial results for the full-year ended December 31, 2020 and provided a corporate update. “In 2020, we successfully completed one of the fastest seed to IPOs in biotech history and made significant strides in advancing our pipeline initiatives, next-generation technology platforms and manufacturing strategy,” said RA Session II, President, Founder and CEO o

    3/3/21 7:00:00 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Taysha Gene Therapies Continues to Add Significant Gene Therapy Expertise to Leadership Team with the Appointment of Chief Legal Officer and Chief People Officer

    DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations, today announced new additions to its leadership team with the appointments of Timothy J. Douros, J.D., as Chief Legal Officer and Corporate Secretary and Tracy M. Porter, M.Ed., SPHR, as Chief People Officer. Mr. Douros will lead all aspects of the company’s legal organization. Ms. Porter will oversee all aspects of human resources, including operations, talent acquisition and employee development.

    1/26/21 7:00:00 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TSHA
    Financials

    Live finance-specific insights

    View All

    Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    TSHA-102 granted Breakthrough Therapy designation by FDA Finalized FDA alignment on REVEAL pivotal trial protocol and SAP, including 6-month interim analysis that may expedite BLA submission, which was enabled by the rigorous developmental milestone evaluation in Part A REVEAL Phase 1/2 trials showing an unprecedented response rate Dosing of first patient in REVEAL pivotal trial scheduled for Q4 2025, with enrollment of additional patients expected to continue at multiple sites this quarter Presented new supplemental analysis of Part A REVEAL data reinforcing the broad and consistent, multi-domain impact of TSHA-102 on activities of daily living at the CNS Annual Meeting TSHA-102

    11/4/25 7:00:00 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4

    DALLAS, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the third quarter ended September 30, 2025, and host a corporate update conference call and webcast on Tuesday, November 4, 2025, at 8:30 AM Eastern Time. Conference Call DetailsTuesday, November 4, at 8:30 AM Eastern Time / 7:30 AM Central TimeToll Free: 800-245-3047International: 203-518-9765Conference ID: TAYSHAWebcast: https://ir.tayshagtx.com

    10/28/25 8:00:00 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    Commenced site activation for REVEAL pivotal trial in accordance with previously aligned upon key design elements, following receipt of No Objection Letter (NOL) from Health Canada and feedback from the FDA; patient enrollment anticipated to begin in Q4 2025 High dose and low dose TSHA-102 continue to be generally well tolerated with no treatment-related SAEs or DLTs in the 12 patients treated in Part A of REVEAL Phase 1/2 trials as of August 2025 data cutoff Part A data from REVEAL Phase 1/2 trials presented at IRSF Scientific Meeting showed 100% response rate for pivotal trial primary endpoint of gain/regain of ≥ one developmental milestone, corroborated by improvements in key secondary

    8/12/25 8:01:00 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TSHA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Taysha Gene Therapies Inc.

    SC 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)

    11/14/24 5:51:11 PM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Taysha Gene Therapies Inc.

    SC 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)

    11/14/24 5:46:12 PM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Taysha Gene Therapies Inc.

    SC 13G - Taysha Gene Therapies, Inc. (0001806310) (Subject)

    11/14/24 9:40:52 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care